Background {#Sec1}
==========

Heart Failure (HF) is a serious condition worldwide, with around 5.7 million people in United States of America being the victims. Also, the disease was found to be a contributing cause in more than 280,000 deaths (1 in 9) in 2008 \[[@CR1]\].The American Heart Association has also suggested about half of people who have heart failure die within 5 years of diagnosis \[[@CR1]\] and hence the problem should not be neglected. It has been reviewed that the population suffering from heart failure is expanding in Asia, particularly in areas like Hong Kong, due to improved living standards \[[@CR2]\]. In Hong Kong, cardiovascular diseases rank the second leading cause of death in age group 65 or above according to the Department of Health \[[@CR3]\]. These findings imply primary interventions must be carried out promptly to deal with the problem, in accordance with the Heart Failure Society of America (HFSA) suggestion that early identification and treatment of risk factors are recognized of utmost importance in limiting the public health impact of heart failure \[[@CR4]\].

It has been investigated that hypertension \[[@CR4], [@CR5], [@CR7]\], diabetes mellitus \[[@CR4], [@CR5], [@CR6], [@CR7]\] and hyperlipidemia \[[@CR4], [@CR6]\] are the major causes of HF. To effectively prevent HF, blood pressure (BP), blood glucose and cholesterol level shall be closely monitored and controlled. Moreover, medication compliance plays an incumbent role to achieve desirable therapeutic outcomes \[[@CR7]\]. It reduces incidents of hospitalization as well as the healthcare cost \[[@CR8]\] in community elderly patients, their compliance to medical regimen shall be emphasized to prevent HF. A foreign study has shown that home-based intervention performed by pharmacists could significantly reduce mortality and recurrent hospitalization in HF patients \[[@CR9]\]. Meanwhile, local studies suggest that a pharmacy outreach service (POS) for community elderly patients can effectively improve BP control \[[@CR10]\] and drug related problems (DRPs) \[[@CR11]\]. Besides, it has been illustrated that pharmacists have an established role in managing DRPs in elderly patients, including drug-drug interactions and therapeutic duplications \[[@CR12]\]. This study aimed to investigate the role of pharmacist intervention in the early identification of HF symptoms in high-risk elderly patients in the community. We therefore conducted a series of POS visits to perform pharmacist interventions on managing the risk factors of HF in the high-risk community elderly patients, hypertension, diabetes, hyperlipidemia as well as reviewing their medication compliance, for the prevention of HF.

Methods {#Sec2}
=======

This was a prospective uncontrolled study of which subjects were recruited from seven elderly centers in Hong Kong during the Pharmacy Outreach Service in July and August 2012. Patients with recent symptoms of HF were included in this study. These symptoms were evaluated by a questionnaire designed to correspond to the New York Heart Association (NYHA) functional classification of HF. High-risk subjects would also be selected, defined as two out of three of the following criteria were met:High blood pressure as defined in Joint National Committee (JNC) 7 \[[@CR13]\]: ≥ 130/80mmHg for diabetic patients and ≥ 140/90mmHg for non-diabetic patientsHigh blood glucose as defined in Standard of Medical Care in Diabetes 2012 \[[@CR14]\]: RCBG ≥ 11.1mmol/LDyslipidemia as defined in ATP III \[[@CR15]\]: LDL level ≥ 2.59mmol/L or TG ≥ 2.3mmol/L

Patients who were younger than 65 years old or diagnosed with the following medical conditions, namely malignancies, dementia, psychiatric disorders, Alzheimer's diseases, Parkinson's diseases or epilepsy, were excluded in the study. Patients without the need of pharmacological management of their hypertension, diabetes, or dyslipidemia were also excluded. Other exclusion criteria include previous participations in the Chinese University of Hong Kong (CUHK) Outreach Service, current involvement in other clinical trials and the presence of communication barriers. The current project was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster (CUHK-NTEC) Clinical Research Ethics Committee (Reference number: 2014.012). All recruited subjects had been consented prior to joining the current project.

Subjects were revisited twice every 3 to 4 months from October 2012 to November 2012 and from February 2013 to April 2013. At each visit, subjects' BP, RCBG level and cholesterol level were measured, and their demographic data and medication profiles were reviewed and recorded. The Omron HEM-7011 electronic blood pressure monitor (Omron Healthcare, Kyoto, Japan) was used for measuring the blood pressure. This electronic device had achieved an "A/A" performance classification under the British Hypertension Society criteria and passed the Association for the Advancement of medical instrumentation requirements \[[@CR16]\]. The random blood glucose level was measured with Accu-Chek® Performa (Roche Diagnostics, Switzerland). The lipid panel of each subject was measured with a CardioChek® Analyzer (Polumer Technology Systems Inc., USA). By using the battery-operated analyzer, four categories of measurements were collected, namely total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL) and triglyceride (TG), from fingerstick capillary samples \[[@CR17]\]. The test system is intended for in vitro diagnostic use to test whole blood \[[@CR18]\].

The workflow of each visit is summarized in Fig. [1](#Fig1){ref-type="fig"}. Pharmacists counseled on the use of medications, disease knowledge and provided non-pharmacological measures for disease management. Interventions were made with regard to any DRPs identified. Additionally, evaluation on signs and symptoms of HF by a questionnaire (Additional file [1](#MOESM1){ref-type="media"}) corresponding to the NYHA functional classification and assessment on medication compliance by the Morisky 8-item Medication Adherence Scale were performed at the first and last visit.Fig. 1Workflow of each visit

The baseline data were compared to those obtained in the last follow-up visit in order to analyze the impacts of POS on community elders' management of risk factors associated with HF. McNemar's test was used for the assessment of HF symptoms while paired t-test was utilized to detect changes in BP, RCBG, cholesterol levels and Morisky Medication Adherence Scale. According to previous POS studies \[[@CR19]--[@CR21]\], mean standard deviation of the change of systolic and diastolic blood pressures are 10.67 and 8.55mmHg respectively.
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At least 40 subjects would be required to identify a 10mmHg change of the systolic blood pressure and at least 26 subjects would be needed to identify a change in 10mmHg of diastolic blood pressure with a power of 80%, a significance level of 0.05 and with an assumption of 40% drop-out rate. Therefore, at least 66 subjects would be required.

All statistical analysis were performed using SPSS 16.0 and a *p* value of \<0.05 was defined as statistically significant.

Results {#Sec3}
=======

We screened 297 patients and a total of 103 patients were recruited. The demographic characteristics and medical history of participants is summarized in Table [1](#Tab1){ref-type="table"}. The mean age of participants was 78.19 ± 6.87 years old, and they were taking an average of 5.08 ± 3.02 chronic medications. For the HF symptoms assessment, a significant increase in number of 31.88% subjects (*p* \< 0.001) were found to be free of symptoms of HF, spanning the period between baseline and the last visit. A significant reduction of mean number of HF symptoms experienced by each subject was observed (*p* \< 0.001). In addition, there were fifteen less elderly patients (-21.74%, *p* = 0.001, Table [2](#Tab2){ref-type="table"}) experienced four or more symptoms at the end of the study. It was observed that more than half (52.17%) of the subjects reported to have limitation of physical activity at baseline and the number was significantly reduced at the end of the study (-26.09%, *p* = 0.001) based on the questionnaire. The other HF symptoms that were found to be sensitive to pharmacist intervention included, shortness of breath (-18.84%, *p* = 0.004), fatigue easily (-17.39%, *p* = 0.029), edema (-17.39, *p* = 0.008) and physical activity limitation when climbing stairs in particular (-18.84%, *p* = 0.015) (Table [2](#Tab2){ref-type="table"}).Table 1Baseline characteristics of the study participantsSubject characteristicsN = 103 (%)Age, mean ± SD, years78.19 ± 6.87Male sex31 (29.66)Literate83 (80.58)Live alone37 (35.92)Smoking Never80(77.67) Quitted19(18.45) Current2(1.94) Unknown2(1.94)Exercise HabitAmount per week,mean ± SD, minutes243.43 ± 202,19 - Less than 150 min per day36(34.95)  − 150 min or above62 (60.19) - Unknown5 (4.85)Disease Status at baseline visitUncontrolled blood pressure level57 (55.34) - Stage II Hypertension^a^19/57 (33.33)Uncontrolled RCBG level^b^20(19.42)Uncontrolled cholesterol levels56(54.37) - Uncontrolled LDL-C level^c^21/56(37.50) - Uncontrolled TG level^d^46/56 (82.14) - Both uncontrolled LDL-C and TG levels11/56(19.64)Present with symptoms of heart failure corresponding to NYIIA Functional Classification system87 (84.47)Medical historyHypertension97 (94.17)Diabetes mellitus44 (42.72)Hyperlipidemia76(73.79)Coronary Heart Disease20(19.42)Heart failure4(3.88)Stroke13(12.62)MedicationsNumber of chronic medications, mean ± SD5.08 ± 3.02a: Non-stage II - Systolic blood pressure \< 160mmHg Or Diastolic blood pressure \< 100mmHgStage II - Systolic blood pressure≧160mmHg Or Diastolic blood pressure≧100mmHg (JNC 7 Guideline \[[@CR13]\])b: Uncontrolled RCBG level: ≥ 11.1 mmol/L (ADA \[[@CR14]\])c: Uncontrolled LDL-C level: ≥ 2.59 mmol/L (ATP III \[[@CR15]\])d: Uncontrolled TG level : ≥ 2.3mmol/L (ATP III \[[@CR15]\])Table 2Summary of various heart failure symptoms experienced by subjects based on the heart Failure Symptoms Assessing Questionnaire at baseline and latest follow-up visit, N = 69Question no.Symptoms of heart failureBaseline n(%)Latest visit, n(%)Difference, n(%)*P* value1Chest pain22 (31.88)13(18.84)−9 (13.04)0.0642Shortness of breath22 (31.88)9(13.04)−13 (18.84)**0.004**3Dyspnea10 (14.49)5 (7.25)−5(7.25)0.1254Dizziness or fainting when position changed18 (26.09)10 (14.49)-8 (11.59)0.0575Dyspnea when. lying down3 (4.35)5 (7.25)+2 (2.90)0.7276Fatigue easily35 (50.72)23 (33.33)−12 (17.39)**0.029**7Edema22 (33.33)11 (15.94)−12(17.39)**0.008**8Sleeping pattern disturbed due to difficulty breathing10 (14.49)7(10.14)−3 (4.35)0.5499Idiopathic cough10 (14.49)4 (5.80)−6(8.70)0.10910Limitation of physical activity36 (52.17)18 (26.09)−18 (26.09)**0.001**10a- Discomfort when climbing stairs31 (49.28)18 (26.09)−13 (18.84)**0.015**10b- Discomfort when walking9(13.04)5 (7.25)-4 (5.80)0.34410c- Discomfort at rest2 (2.90)5 (7.25)+3 (4.35)0.375Total no. of subject symptoms of heart failure63 (91.30)41 (59.42)−22 (31.88)**\<0.001**No. of symptoms experienced by individual, mean ± SD2.96 ± 1.931.52 ± 1.91−1.43 ± 1.90**\<0.001**Symptoms experienced by most subjectsLimitation of physical activityFatigue easily2^nd^ most symptoms experienced by subjectsFatigue easilyLimitation of physical activityNo. of subjects experienced1 symptom10 (14.49)15(21.74)+5 (7.25)0.2252 symptoms14 (3.0.29)9(13.04)−5(7.25)0.2513 symptoms15 (21.74)8 (11.59)−7 (10.14)0.108≥4 symptoms24 (34.73)9(13.04)−15(21.74)**0.001**

For the impact of POS on the risk factors management of heart failure, namely hypertension, diabetic mellitus and hyperlipidemia, no significant improvement was observed in BP and glycemic control in overall participants. However, significant reduction in SBP level (-14.45 ± 17.97mmHg, *p* = 0.024) was achieved in subjects with Stage II hypertension. The reduction of RCBG level (-3.70 ± 2.44mmol/L, *p* = 0.004) was also significant in not well-controlled subjects (Table [3](#Tab3){ref-type="table"}). For lipid control, significant improvement was achieved in overall participants, with significant reduction in LDL-cholesterol level (-0.86 ± 0.56mmol/L, *p* = 0.038), and in triglyceride level (-1.15 ± 1.09mmol/L, *p* \< 0.001).Table 3Comparison of blood pressure, random capillary blood glucose and cholesterol level between baseline and the latest follow-up visitSystolic blood pressure (SBP) level (mean ± SD, mmHg)NBaselineLatestDifference*P* valueAll61142.11 ± 19.73145.00 ± 19.37+2.89 ± 22.020.310Uncontrolled subject^a^11169.27 ± 11.59154.82 ± 16.32−14.45 ± 17.97**0.024**Diastolic blood pressure (DBP) level (mean ± SD, mmHg)All6170.20 ± 10.7071.87 ± 9.54+1.67 ± 10.350.256Uncontrolled subject^a^1171.00 ± 9.9672.45 ± 11.24+1.24 ± 13.490.728Random capillary blood glucose (RCBG) level (mean ± SD, mmol/L)All617.81 ± 2.797.78 ± 2.89−0.03 ± 2.960.938Uncontrolled subject^b^813.45 ± 2.579.75 ± 3.63−3.70 ± 2.44**0.004**LDL-cholesterol level (mean - SD, mmol/L)All572.23 ± 0.912.05 ± 0.57−0.19 ± 0.66**0.038**Uncontrolled subject^c^173.42 ± 0.542.56 ± 0.46−0.86 ± 0.56**\<0.001**Triglyceride level (mean ± SD, mmol/L)All602.40 ± 1.111.71 ± 0.90−0.68 ± 1.01**\<0.001**Uncontrolled subject^d^303.28 ± 0.862.13 ± 1.00−1.15 ± 1.09**\<0.001**a: uncontrolled subjects with SBP/DBP \>140/90 mmHg or \>130/80 mmHg (DM patients) (JNC 7 \[[@CR13]\])b: uncontrolled subjects" with baseline RCBG \> 11.1 mmol/L (ADA \[[@CR14]\])c: uncontrolled subjects with LDL-level \> 2.59 mmol/L(ATP III \[[@CR15]\])d: uncontrolled subjects with TG-level \>2.3 mmol/L(ATP III \[[@CR15]\])

Non-compliance to medications is also a contributing factor of HF, 66.99% of the elderly patients were identified to be medication non-compliant. The Morisky score results showed a significant reduction in mean score by 0.54 ± 1.50 (*p* = 0.005) (Table [4](#Tab4){ref-type="table"}). At the baseline, 27.54% of the subjects were considered as low compliance subjects and there was a slight but insignificant reduction in the number at the end of the study (-4.35%, *p* = 0.607). In addition, results showed a significant increase by 23.19% (*p* = 0.001) in the number of subjects with high compliance level. Forgetfulness (30.4%) was found to be the most common reason for non-compliance, followed by improper administration time (20.3%) and fear of adverse drug reaction (18.8%).Table 4Identified causes of non-compliance and the compliance score at Baseline and the latest Follow-up visit, N = 69Causes of non-complianceN (%)Forgetfulness21/69 (30.43)Dosage adjustment8/69(11.59)Frequency adjustment8/69(11.59)Improper administration time14/69 (20.29)Improper administration method3/69 (4.35)Overuse of "PRN" drugs3/69 (4.35)Underuse of "PRN" drugs1/69(1.45)Fear of Adverse drug reaction13/69(18.84)Think no need7/69(10.14)Pill splitting method2/69 (2.9)Compliance score^J^BaselineLatestDifference*p* valuemean ± SD1.93(±1.78)1.39(±1.80)−0.54(±1.50)**0.005**No. of Low adherence subject^k^,n(%)19 (27.54)16(23.19)−3 (4.35)0.607No. of Medium adherence subject^k^', n (%)33 (47.83)20 (28.99)−13(18.84)**0.011**No. of High adherence subject^k^, n (%)17(24.64)33 (47.83)+16(23.19)**0.001**J: Compliance based on Morisky questionnairek: Low adherence - Morisky Scores \>2; Medium adherence - Morisky Scores = 1 or 2; High adherence - Morisky Scores = 0

Discussion {#Sec4}
==========

It has been suggested by HFSA that patients at risk of cardiovascular disease are also at high risk for developing HF, and early identification and treatment of risk factors are recognized of utmost importance in limiting the public health impact of HF \[[@CR4]\]. Hypertension, hyperlipidemia, diabetes mellitus and unhealthy lifestyle are recognized as potential risk factors for the development of myocardial remodeling, cardiac dysfunction and hence HF. In the study, subjects were being assessed with the presence of HF symptoms using the HF Symptoms Assessment Questionnaire via self-reporting method. There were a total of 16 questions in the questionnaire that correspond to ten symptoms of HF. Significant reduction in number of HF symptoms experienced by each subject as well as number of subjects experienced four or more symptoms were observed, which demonstrated the changes before and after the pharmacists' interventions. Although the changes may not be solely due to the pharmacists' intervention due to the lack of control group in the current study. It demonstrated the potential essential role of pharmacist intervention upon better disease control and minimizing risk of HF in community elderly patients. These results correlate to a previous study suggesting that pharmacists have an incumbent role in the community in HF management \[[@CR16]\].

In addition, the role of pharmacist in managing risk factors of HF was also investigated in the study. According to the US NHANES I Epidemiologic Follow-up Study, not well-controlled hypertension was found to be positively and significantly associated to increased risk of HF \[[@CR17]\]. This study has shown no significant improvement in the BP management in overall participants, however in subgroup analysis, statistically significant reduction in SBP level was detected in participants with stage-II hypertension at baseline. This result is consistent with a previous study which has shown that hypertensive patients with baseline SBP ≥160mmHg would have a more significant decrease in BP than the others who have lower BP baseline after pharmacist intervention \[[@CR25]\]. Therefore, hypertensive patients, who are of higher risk to developing HF, are more sensitive to pharmacist intervention in the prevention of HF.

It was clearly established in prior studies that diabetes is a risk factor for HF \[[@CR26]-[@CR29]\]. In the study, no significant improvement in glycemic control was observed in overall participants. The reason for the insignificant result might be due to the fact that RCBG level was highly subjected to the influence of various confounding factors, such as time elapsed after food intake. As a result, RCBG level might not able to truly reflect the impact of pharmacist intervention on glycemic control in overall participants. Improvement in study design, such as measuring HbA1c level instead of RCBG level, is suggested in future investigation.

HFSA has suggested that hyperlipidemia is a risk factor for the development of HF \[[@CR4]\]. Meanwhile, since hyperlipidemia is one of the risk factors for the development of CHD \[[@CR30]\], well control of cholesterol levels, particularly LDL-cholesterol level, can reduce risk of CHD and subsequently myocardial remodeling and heart failure. This study has showed that pharmacist intervention significantly reduce LDL-cholesterol level as well as triglyceride level in overall participants. In the sub-group analysis, subjects with not well-controlled cholesterol levels were found to be more sensitive to pharmacist intervention in managing hyperlipidemia. Precedent studies have found that regular pharmacist follow-up and intervention for patients on disease education, cholesterol measurement, medication compliance and referral to physician can improve cholesterol management in high-risk patients \[[@CR31], [@CR32]\]. Systemic review also showed that community pharmacy-based service contributed to the reduction in risk factors for CHD regarding lipid management \[[@CR17]\]. Therefore, pharmacist intervention in POS may contribute in prevention HF in community elderly patients but further investigation shall be conducted to provide solid evidence on this issue.

Several studies have suggested that non-compliance can be a precipitating factor of HF exacerbation \[[@CR18], [@CR33]\] as well as impairing the chronic disease management \[[@CR34]\]. Pharmacist therefore are in ideal position to evaluate patients' compliance and aid them to improve their medication compliance. Therefore, it is essential for pharmacist to ensure patients with chronic diseases are compliance with medications to prevent HF or its progression. In this study, the Morisky score results showed a significant improvement in medication compliance among subjects with pharmacist intervention, which provide medical education on individual's regimen. Over 66% of subjects were identified to have non-compliance issue, which is one of the well-known common DRPs in elderly patients \[[@CR35]\]. Out of the various reasons behind the non-compliance issue, forgetfulness contributed the most (30.4%). Forgetfulness is classified as an unintentional cause of non-compliance. Previous study \[[@CR36]\] illustrates the importance of pharmacist's intervention in providing memory aids, educating measures to take if a dose is missed and suggesting the use of medication compliance calendars. Therefore, additional compliance aids and education shall be provided in the future POS.

Limitations {#Sec5}
-----------

The current study has several limitations. There was selection bias during sampling since this was not a randomized trial, which was also reflected in the unequal distribution in gender in the sample. There were more female subjects involved in the POS probably due to their better health-seeking behavior but this was consistent with the previous POS \[[@CR10]\]. A randomized controlled trial with cross-over design might be considered not only to reduce the selection bias but also to provide a more concrete evidence for the benefits of pharmacist interventions. Furthermore, only seven elderly centers participated in this study and this may not be truly reflecting the situation in Hong Kong. We did not assess the echocardiography results to confirm the impact of POS. The compliance assessment was based on self-reporting from the patients. The current HF questionnaire developed for this study was not validated and therefore may not be applicable for patients outside Hong Kong. Not all risk factors were examined in this study. The sample size of the current study was small and Hong Kong-based. As a result, the study may be underpowered and not be able to generalize to other countries with a larger population.

Conclusion {#Sec6}
==========

Pharmacy outreach service has significantly improved HF symptoms management and medication compliance in the high-risk community elderly patients. It has also improved cholesterol management in overall subjects. Further investigation with improved study design shall be conducted in order to evaluate and provide sound evidence on pharmacist role in preventing HF in community elderly patients.
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